Pooled Analysis of S-1 Trials in Non-Small Cell Lung Cancer According to Histological Type
+ }. n P9 B+ j) P- @8 h1 e: uNOBUYUKI YAMAMOTO1, TAKEHARU YAMANAKA2, YUKITO ICHINOSE3, KAORU KUBOTA4, HIROSHI SAKAI5, AKIHIKO GEMMA6, NAGAHIRO SAIJO7, MASAHIRO FUKUOKA8 and HISANOBU NIITANI9
* v# R8 d6 U, d8 S. {. g1 A' f( l# v+ Author Affiliations
1 t4 Q2 D# t) C( V# v( f% g1 M: T' l2 u% `3 U, |% f
1Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan 5 N4 Z# e5 [+ L, g6 z) d6 I' T; v3 d
2Cancer Biostatistics Laboratory, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka 811-1395, Japan 0 D0 N0 `. ]) r0 p% w
3Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan ! x" A, ?+ j L: f* e
4Division of Thoracic Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan ) v/ u% u& N6 T) H( a
5Division of Thoracic Oncology, Saitama Cancer Center, Saitama 362-0806, Japan ) }. N% E" A4 N4 V
6Division of Pulmonary Medicine, Infectious Diseases, and Oncology Department of Internal Medicine, Nippon Medical School, Tokyo 113-8603, Japan : Q; o6 b! A8 |! P6 m' Q6 s1 l
7Kinki University School of Medicine, Osaka 589-8511, Japan
8 e) L f6 v" d8Izumi Municipal Hospital, Osaka 594-0071, Japan
$ B% C1 X" ~3 K( K6 Y. x9Tokyo Cooperative Oncology Group, Tokyo 105-0013, Japan
/ D9 O- L% _" O/ f9 F. qCorrespondence to: Nobuyuki Yamamoto, Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan. Tel: +81 559895222, Fax: +81 559895783, e-mail: n.yamamoto@scchr.jp % [8 D3 e, [) X8 }* K/ m
AbstractBackground: The antimetabolic agent S-1 inhibits thymidylate synthase similar to pemetrexed, but through a different mechanism of action. Whether the antitumour activity of S-1 depends on histological type remains unclear. We analysed pooled data from 2 phase II clinical studies of cisplatin and S-1 in patients with previously untreated advanced non-small cell lung cancer. Patients and Methods: We comprised 110 patients with stage IIIB or IV non–small cell lung cancer. Univariate and multivariate analyses were performed to determine the effects of histological type on progression-free survival and response rates. Results: On pooled analysis of the data, according to histological type, median progression-free survival was 3.8 months in patients with squamous cell carcinoma and 4.4 months in those with non-squamous cell carcinoma. Both analyses showed that progression-free survival and response rate did not differ significantly. Conclusion: Unlike molecular targeted agents and pemetrexed, a combination of cisplatin and S-1 may be no difference in response according to histological type. 1 d. ]4 S. f4 j0 m+ I; U& B
# K- @- h3 d3 B2 t B# H |